Brussels, 14/10/2011 (Agence Europe) - On Friday 14 October, the European Commission cleared the acquisition of US-based pharmaceutical company Cephalon by the generic pharmaceutical company Teva of Israel. The decision is conditional upon the divestment of Cephalon's generic version of its “Provigil” drug. Provigil is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy.
The Commission examined the effects of the planned deal on the market for drugs...